4//SEC Filing
Snyder Mark Howard 4
Accession 0001415889-25-004508
CIK 0001159036other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 6:41 PM ET
Size
14.2 KB
Accession
0001415889-25-004508
Insider Transaction Report
Form 4
Snyder Mark Howard
SVP, CHIEF LEGAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-02-16+17,409→ 32,411 total - Tax Payment
Common Stock
2025-02-16$58.29/sh−9,373$546,352→ 23,038 total - Exercise/Conversion
Common Stock
2025-02-16+4,796→ 27,834 total - Tax Payment
Common Stock
2025-02-16$58.29/sh−2,582$150,505→ 25,252 total - Exercise/Conversion
Performance Stock Units
2025-02-16−17,409→ 0 totalExercise: $0.00→ Common Stock (17,409 underlying) - Exercise/Conversion
Restricted Stock Units
2025-02-16−4,796→ 9,592 totalExercise: $0.00→ Common Stock (4,796 underlying)
Footnotes (4)
- [F1]The reported disposition of 9,373 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
- [F2]The reported disposition of 2,582 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
- [F3]This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.
- [F4]This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Documents
Issuer
HALOZYME THERAPEUTICS, INC.
CIK 0001159036
Entity typeother
Related Parties
1- filerCIK 0001902866
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 6:41 PM ET
- Size
- 14.2 KB